ArticleGut pathogens2025
Nasopharyngeal viral infection as a source of elevated fecal calprotectin: a diagnostic pitfall in intestinal inflammation.
Article in Gut pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fecal calprotectin is widely used as a non-invasive biomarker for intestinal inflammation, particularly in inflammatory bowel disease (IBD), the most common clinical context for its use, where misinterpretation can lead to unnecessary invasive procedures or inappropriate therapy escalation. However, its specificity has been questioned due to elevated levels observed in non-intestinal conditions. Here, we investigated whether nasopharyngeal viral infections contribute to elevated fecal calprotectin, thereby confounding its diagnostic interpretation. Bioinformatic analysis revealed high constitutive expression of calprotectin subunits (S100A8/A9) in squamous epithelia of the upper aerodigestive tract compared with distal gut mucosa. To assess gastrointestinal stability of epithelial-derived calprotectin, healthy volunteers ingested porcine calprotectin, which was subsequently detected in feces, demonstrating resistance to intestinal degradation. In a retrospective cohort, patients with non-SARS-CoV-2 respiratory viral infections displayed significantly higher fecal calprotectin levels than SARS-CoV-2 patients (447 µg/g vs. 82 µg/g, p < 0.001), despite limited gastrointestinal involvement. Nasopharyngeal calprotectin levels did not differ significantly between viral etiologies, but in COVID-19 patients, fecal calprotectin positively correlated with nasopharyngeal calprotectin (R = 0.43, p = 0.008) and viral load (R = 0.13, p = 0.026). These findings suggest that calprotectin released from proximal epithelial tissues during viral infection can persist through the gastrointestinal tract and influence fecal calprotectin levels, underscoring the importance of contextual interpretation of this biomarker and the value of incorporating virological assessment into diagnostic workflows.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.